Affiliations
AffiliationItem in Clipboard
Stitching the gaps in the Canadian public drug coverage patchwork?: a review of provincial pharmacare policy changes from 2000 to 2010Jamie R Daw et al. Health Policy. 2012 Jan.
doi: 10.1016/j.healthpol.2011.08.015. Epub 2011 Oct 5. AffiliationItem in Clipboard
AbstractObjectives: To describe recent changes and identify emergent trends in public drug benefit policies in Canada from 2000 to 2010.
Methods: For each province, we tracked pharmacare design (namely eligibility, premiums, and patient cost-sharing) over time for three beneficiary groups: social assistance recipients, seniors, and the general non-senior population. We assess which plan designs are emerging as a national standard, where the gaps in public coverage remain, and implications for progress towards national pharmacare.
Results: Expansion of public drug coverage has been limited. For social assistance recipients, first-dollar coverage is the standard. Seniors coverage remains varied, though means testing of eligibility or cost-sharing is common. Seniors benefits were significantly expanded in only one province. As of 2010, six provinces have embraced age irrelevant catastrophic income-based coverage, in some, resulting in the elimination of seniors drug benefits.
Conclusions: Universal income-based catastrophic coverage appears to be emerging as an implicit national standard for provincial pharmacare. However, due to the variation and high level of patient cost-sharing required under these programs, convergence on this model does not equate to substantial progress towards expanding coverage or reducing interprovincial disparities. Leverage of federal spending power to promote standards for public drug coverage is necessary to uniformly protect Canadians against high drug costs.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.
Conflict of interest statementConflict of Interest
The authors have no conflicts of interest to declare.
FiguresFigure 1
Cost sharing structure for social…
Figure 1
Cost sharing structure for social assistance beneficiaries by province, 2000–2010. Notes: AB: Co-payment…
Figure 1Cost sharing structure for social assistance beneficiaries by province, 2000–2010. Notes: AB: Co-payment of $2.00 for the first three prescriptions per month was eliminated in May 2004. QB: Deductibles and co-insurance for all welfare recipients were eliminated on July 1, 2007.
Figure 2
Cost sharing structure for seniors…
Figure 2
Cost sharing structure for seniors (>=65) by province, 2000–2010. Notes: BC: Fair…
Figure 2Cost sharing structure for seniors (>=65) by province, 2000–2010. Notes: BC: Fair Pharmacare was introduced in May 2003, replacing both the Universal Plan (Plan E) and the Seniors Plan (Plan A). SK: The Senior’s Drug Plan was introduced on July 1, 2007. The plan required seniors to pay a $15 co-payment for all drugs listed on the SK formulary. As of July 1, 2008, an income-based eligibility test was introduced. Only seniors with a reported income that is less than the limit for the federal age credit are eligible (individual net income less than $75,480 in 2010). QB: As of July 1, 2005, all patient cost sharing was removed for seniors receiving the maximum GIS. As of July 1, 2007, cost sharing was removed for seniors receiving 94 to 99% of the GIS. NL: The 65Plus Plan covers only seniors eligible for both old age security and the GIS (individual net income less than $15,888 required to qualify for the GIS in 2011). The universal catastrophic Assurance Plan was introduced on October 31, 2007.
Figure 3
Cost sharing structure for the…
Figure 3
Cost sharing structure for the general non-senior population by province, 2000–2010. Notes: BC:…
Figure 3Cost sharing structure for the general non-senior population by province, 2000–2010. Notes: BC: Fair Pharmacare was introduced in May 2003, replacing both the Universal Plan (Plan E) and the Seniors Plan (Plan A). NS: Nova Scotia Family Pharmacare was introduced on March 1, 2008. NL: The Assurance Plan was introduced on October 31, 2007.
Similar articlesGrootendorst P. Grootendorst P. Can J Clin Pharmacol. 2002 Summer;9(2):79-99. Can J Clin Pharmacol. 2002. PMID: 12172588
McLeod L, Bereza BG, Shim M, Grootendorst P. McLeod L, et al. Open Med. 2011;5(1):e1-9. Epub 2011 Jan 4. Open Med. 2011. PMID: 22046212 Free PMC article.
Hajizadeh M, Edmonds S. Hajizadeh M, et al. Int J Health Policy Manag. 2020 Mar 1;9(3):91-95. doi: 10.15171/ijhpm.2019.93. Int J Health Policy Manag. 2020. PMID: 32202091 Free PMC article.
Morgan SG, Boothe K. Morgan SG, et al. Healthc Manage Forum. 2016 Nov;29(6):247-254. doi: 10.1177/0840470416658907. Epub 2016 Oct 15. Healthc Manage Forum. 2016. PMID: 27744279 Free PMC article. Review.
Brandt J, Shearer B, Morgan SG. Brandt J, et al. J Pharm Policy Pract. 2018 Nov 7;11:28. doi: 10.1186/s40545-018-0154-x. eCollection 2018. J Pharm Policy Pract. 2018. PMID: 30443371 Free PMC article. Review.
Campbell DJ, Manns BJ, Hemmelgarn BR, Sanmartin C, King-Shier KM. Campbell DJ, et al. CMAJ Open. 2016 Jun 8;4(2):E304-8. doi: 10.9778/cmajo.20160030. eCollection 2016 Apr-Jun. CMAJ Open. 2016. PMID: 27398378 Free PMC article.
Tang KL, Ghali WA, Manns BJ. Tang KL, et al. CMAJ. 2014 Mar 4;186(4):276-80. doi: 10.1503/cmaj.121637. Epub 2013 Sep 16. CMAJ. 2014. PMID: 24043654 Free PMC article. No abstract available.
Morgan SG, Daw JR. Morgan SG, et al. Healthc Policy. 2012 Aug;8(1):14-23. Healthc Policy. 2012. PMID: 23968600 Free PMC article.
Morgan SG, Friesen MK, Thomson PA, Daw JR. Morgan SG, et al. Healthc Policy. 2013 May;8(4):45-55. Healthc Policy. 2013. PMID: 23968637 Free PMC article.
Edmonds S, Hajizadeh M. Edmonds S, et al. Eur J Health Econ. 2019 Sep;20(7):1001-1011. doi: 10.1007/s10198-019-01074-x. Epub 2019 May 28. Eur J Health Econ. 2019. PMID: 31140059
RetroSearch is an open source project built by @garambo | Open a GitHub Issue
Search and Browse the WWW like it's 1997 | Search results from DuckDuckGo
HTML:
3.2
| Encoding:
UTF-8
| Version:
0.7.3